Tuberculosis diagnostics: which target product profiles should be prioritised?
Authors:
Open Access
- 2 April 2014
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 44 (2) , 537-540
Abstract
Over the last decade, there has been a steady increase in the use of fixed-dose combinations of drugs for the treatment of a range of diseases, including hypertension, cancer, AIDS, tuberculosis and other infectious diseases. It is now evident that patients with asthma or chronic obstructive pulmonary disease (COPD) can also benefit from the use of fixed-dose combinations, including combinations of a long-acting β2-agonist and an inhaled corticosteroid, and combinations of long-acting β2-agonists and long-acting muscarinic receptor antagonists. In fact, there are now a number of “triple-inhaler” fixed-dose combinations under development, with the first such triple combination having been approved in India. This use of combinations containing drugs with complementary pharmacological actions in the treatment of patients with asthma or COPD has also led to the discovery and development of drugs having two different primary pharmacological actions in the same molecule, which we have called “bifunctional drugs”. In this review, we discuss the state of the art of these new bifunctional drugs as novel treatments for asthma and COPD that can be categorised as bifunctional bronchodilators, bifunctional bronchodilator/anti-inflammatory drugs and bifunctional anti-inflammatory drugs.Keywords
This publication has 9 references indexed in Scilit:
- Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential?European Respiratory Journal, 2014
- Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis InfectionClinical Microbiology Reviews, 2014
- Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countriesExpert Review of Molecular Diagnostics, 2013
- Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?European Respiratory Journal, 2013
- Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for actionThe Lancet Infectious Diseases, 2013
- Tuberculosis biomarkers discovery: developments, needs, and challengesThe Lancet Infectious Diseases, 2013
- Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIFEuropean Respiratory Journal, 2012
- Point-of-Care Testing for Infectious Diseases: Diversity, Complexity, and Barriers in Low- And Middle-Income CountriesPLOS Medicine, 2012
- Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert PanelThe Journal of Infectious Diseases, 2012